Accelerate Diagnostics Inc (NASDAQ:AXDX) was up 7.4% during trading on Tuesday . The stock traded as high as $18.64 and last traded at $18.53, approximately 382,071 shares traded hands during mid-day trading. An increase of 47% from the average daily volume of 259,470 shares. The stock had previously closed at $17.26.

Several research analysts have recently commented on AXDX shares. BidaskClub downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th. BTIG Research reaffirmed a “hold” rating on shares of Accelerate Diagnostics in a research note on Sunday, May 12th. Zacks Investment Research downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. ValuEngine downgraded Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. Finally, Piper Jaffray Companies decreased their price objective on Accelerate Diagnostics from $22.00 to $19.00 and set a “positive” rating on the stock in a research note on Friday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $18.67.

The business’s 50 day moving average is $19.66. The firm has a market capitalization of $965.55 million, a P/E ratio of -11.44 and a beta of 2.75. The company has a debt-to-equity ratio of 2.86, a quick ratio of 24.03 and a current ratio of 25.36.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $2.71 million. Accelerate Diagnostics had a negative return on equity of 146.56% and a negative net margin of 1,293.91%. Equities research analysts expect that Accelerate Diagnostics Inc will post -1.6 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of AXDX. AXA raised its stake in Accelerate Diagnostics by 304.0% during the 2nd quarter. AXA now owns 1,762,505 shares of the medical research company’s stock valued at $40,326,000 after purchasing an additional 1,326,233 shares during the period. C WorldWide Group Holding A S raised its stake in Accelerate Diagnostics by 357.5% during the 2nd quarter. C WorldWide Group Holding A S now owns 524,683 shares of the medical research company’s stock valued at $12,005,000 after purchasing an additional 410,000 shares during the period. Belpointe Asset Management LLC bought a new stake in Accelerate Diagnostics during the 1st quarter valued at approximately $5,728,000. BlackRock Inc. raised its stake in Accelerate Diagnostics by 15.4% during the 2nd quarter. BlackRock Inc. now owns 2,004,650 shares of the medical research company’s stock valued at $45,865,000 after purchasing an additional 267,704 shares during the period. Finally, FMR LLC raised its stake in Accelerate Diagnostics by 25.1% during the 4th quarter. FMR LLC now owns 738,449 shares of the medical research company’s stock valued at $8,492,000 after purchasing an additional 148,099 shares during the period. 51.59% of the stock is currently owned by institutional investors.

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Read More: What are momentum indicators and what do they show?

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.